Skip to main content
TipRanks
Go Ultimate75% OFF

Gyre Therapeutics (GYRE) Ratios

829 Followers

Gyre Therapeutics Ratios

GYRE's free cash flow for Q3 2026 was $-4.96M. For the 2026 fiscal year, GYRE's free cash flow was decreased by $-979.00K and operating cash flow was $-3.98M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Mar 22
Liquidity Ratios
Current Ratio5.603.322.854.063.63
Quick Ratio5.042.992.643.563.63
Cash Ratio2.030.611.672.063.13
Solvency Ratio0.310.51-0.900.27-6.01
Operating Cash Flow Ratio0.06-0.191.290.87-5.91
Short-Term Operating Cash Flow Coverage0.000.000.000.00-42.36
Net Current Asset Value$ 78.52M$ 37.78M$ -45.37M$ 37.12M$ 36.90M
Leverage Ratios
Debt-to-Assets Ratio0.010.010.000.010.04
Debt-to-Equity Ratio0.010.03-0.030.010.06
Debt-to-Capital Ratio0.010.02-0.030.010.05
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.571.98-7.361.991.35
Debt Service Coverage Ratio0.000.000.000.00-44.33
Interest Coverage Ratio0.000.000.000.000.00
Debt to Market Cap0.000.000.000.000.00
Interest Debt Per Share0.010.020.010.010.08
Net Debt to EBITDA-2.14-0.57-1.63-2.380.48
Profitability Margins
Gross Profit Margin95.35%96.33%95.91%95.31%-4.52%
EBIT Margin12.38%15.35%16.94%9.00%-1198.32%
EBITDA Margin14.51%16.85%17.92%10.10%-1194.37%
Operating Profit Margin9.86%15.28%-59.26%9.00%-1140.99%
Pretax Profit Margin12.38%21.95%-67.84%9.20%-1198.32%
Net Profit Margin4.31%11.43%-81.92%2.25%-1198.32%
Continuous Operations Profit Margin8.47%16.92%-75.35%4.22%-1198.32%
Net Income Per EBT34.82%52.05%120.75%24.46%100.00%
EBT Per EBIT125.63%143.65%114.48%102.27%105.02%
Return on Assets (ROA)3.03%9.64%-79.74%2.72%-157.98%
Return on Equity (ROE)4.74%19.09%587.14%5.41%-214.01%
Return on Capital Employed (ROCE)7.77%15.26%-69.67%12.69%-201.76%
Return on Invested Capital (ROIC)5.30%11.69%-69.52%5.78%-192.59%
Return on Tangible Assets3.11%9.77%-80.92%2.78%-157.98%
Earnings Yield0.80%1.17%-5.93%0.38%-21.02%
Efficiency Ratios
Receivables Turnover3.163.636.746.554.04
Payables Turnover43.6835.9613.0639.291.19
Inventory Turnover0.530.611.080.780.00
Fixed Asset Turnover4.714.124.775.571.98
Asset Turnover0.700.840.971.210.13
Working Capital Turnover Ratio1.802.573.042.740.13
Cash Conversion Cycle792.76685.99363.28512.63-215.04
Days of Sales Outstanding115.67100.6254.1855.7290.43
Days of Inventory Outstanding685.45595.52337.05466.210.00
Days of Payables Outstanding8.3610.1527.959.29305.47
Operating Cycle801.12696.14391.23521.9290.43
Cash Flow Ratios
Operating Cash Flow Per Share0.01-0.040.390.14-2.73
Free Cash Flow Per Share-0.00-0.080.260.07-2.76
Dividend Paid and CapEx Coverage Ratio0.85-1.160.110.01-99.83
Capital Expenditure Coverage Ratio0.85-1.163.022.14-99.83
Operating Cash Flow Coverage Ratio1.08-2.2863.3117.42-35.12
Operating Cash Flow to Sales Ratio0.01-0.030.230.10-11.41
Free Cash Flow Yield-0.03%-0.66%1.11%0.93%-20.23%
Valuation Ratios
Price-to-Earnings (P/E) Ratio125.4086.43-16.85265.01-4.76
Price-to-Sales (P/S) Ratio5.419.7413.805.9657.00
Price-to-Book (P/B) Ratio5.9516.26-98.9514.3510.18
Price-to-Free Cash Flow (P/FCF) Ratio-3504.29-152.1190.50107.42-4.94
Price-to-Operating Cash Flow Ratio624.53-282.7960.4957.14-4.99
Price-to-Earnings Growth (PEG) Ratio-2.10-0.790.00-2.622.32
Enterprise Value Multiple35.1557.2275.4256.67-4.29
Enterprise Value594.64M1.02B1.53B585.49M376.29M
EV to EBITDA35.1557.2275.4256.67-4.29
EV to Sales5.109.6413.515.7251.28
EV to Free Cash Flow-3303.57-150.6088.58103.10-4.45
EV to Operating Cash Flow588.75-279.9959.2154.84-4.49
Tangible Book Value Per Share1.541.140.190.921.34
Shareholders’ Equity Per Share1.190.74-0.240.551.34
Tax and Other Ratios
Effective Tax Rate0.320.23-0.110.540.00
Revenue Per Share1.301.241.721.330.24
Net Income Per Share0.060.14-1.410.03-2.87
Tax Burden0.350.521.210.241.00
Interest Burden1.001.43-4.011.021.00
Research & Development to Revenue0.120.110.120.168.80
SG&A to Revenue0.740.700.130.170.00
Stock-Based Compensation to Revenue0.060.010.060.130.46
Income Quality0.10-0.20-0.302.470.95

Currency in USD